We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+6.06%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.28B
AUM Growth
+$142M
Cap. Flow
+$97.5M
Cap. Flow %
7.64%
Top 10 Hldgs %
60.95%
Holding
46
New
10
Increased
10
Reduced
13
Closed
7

Top Buys

Rank Stock Value
1
HAE icon
Haemonetics
HAE
+$45.9M
2
LH icon
Labcorp
LH
+$34.8M
3
CYH icon
Community Health Systems
CYH
+$30M
4
THC icon
Tenet Healthcare
THC
+$26.5M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$23.2M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$72.8M
2
MRK icon
Merck
MRK
+$49.6M
3
A icon
Agilent Technologies
A
+$28.6M
4
UNH icon
UnitedHealth
UNH
+$26.3M
5
EW icon
Edwards Lifesciences
EW
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 71.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRNX
26
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$13M 1.02%
613,655
+363,655
+145% +$7.06M
VTRS icon
27
Viatris
VTRS
$20.4B
$12.2M 0.96%
250,000
-1,500,000
-86% -$72.8M
NXTM
28
DELISTED
NxStage Medical Inc.
NXTM
$10.5M 0.82%
820,535
– –
NVAX icon
29
Novavax
NVAX
$1.2B
$10.2M 0.8%
112,500
-62,500
-36% -$6.98M
GERN icon
30
Geron
GERN
$828M
$9.82M 0.77%
4,972,600
+3,385,600
+213% +$13.5M
RVNC
31
DELISTED
Revance Therapeutics, Inc.
RVNC
$9.45M 0.74%
+300,000
New +$9.37M
PLX icon
32
Protalix BioTherapeutics
PLX
$191M
$9.16M 0.72%
200,000
– –
GNMK
33
DELISTED
GenMark Diagnostics, Inc
GNMK
$9.03M 0.71%
908,100
-41,900
-4% -$521K
GYRE icon
34
Gyre Therapeutics
GYRE
$641M
$7.41M 0.58%
1,981
+1,746
+743% +$6.46M
SQNM
35
DELISTED
SEQUENOM INC NEW
SQNM
$7.13M 0.56%
+2,911,520
New +$6.94M
BIOL
36
DELISTED
Biolase, Inc.
BIOL
$6.54M 0.51%
217
– –
ANGO icon
37
AngioDynamics
ANGO
$611M
$6.49M 0.51%
411,930
-588,070
-59% -$9.58M
MNTA
38
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$4.66M 0.37%
400,000
-400,000
-50% -$6.77M
CCRN
39
DELISTED
Cross Country Healthcare
CCRN
$2.49M 0.2%
308,542
-1,231,458
-80% -$12.1M
A icon
40
Agilent Technologies
A
$39.1B
– –
-699,000
Closed -$28.6M
ARWR icon
41
Arrowhead Research
ARWR
$11.9B
– –
-1,500,000
Closed -$16.3M
EW icon
42
Edwards Lifesciences
EW
$49.6B
– –
-2,100,000
Closed -$23M
MRK icon
43
Merck
MRK
$322B
– –
-1,037,834
Closed -$49.6M
TEVA icon
44
CALL
Teva Pharmaceuticals
TEVA
$40.8B
– –
-2,250,000
Closed -$90.2M
XNPT
45
DELISTED
XENOPORT, INC.
XNPT
– –
-1,000,000
Closed -$5.75M
DSCI
46
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
– –
-497,000
Closed -$5.38M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, Camber Capital Management held 46 positions worth $1.28B, up 13% from $1.13B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Camber Capital Management deployed $97.5M of net new capital in Q1 2014, opening 10 new positions and adding to 10 existing holdings. Its largest new stake was Haemonetics: 1,202,000 shares worth $39.2M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Viatris, an estimated $72.8M trimmed.

  • Camber Capital Management's largest Q1 2014 buy was Haemonetics: 1,202,000 shares worth $39.2M.
  • Camber Capital Management added most to Community Health Systems in Q1 2014, an estimated $30M increase.
  • Camber Capital Management's biggest Q1 2014 reduction was Viatris, cutting an estimated $72.8M.
  • Camber Capital Management fully exited Merck in Q1 2014, selling an estimated $49.6M.
  • Camber Capital Management's ten largest holdings make up 61% of its $1.28B portfolio in Q1 2014.
  • Camber Capital Management opened 10 new positions and closed 7 in Q1 2014.
  • Camber Capital Management's portfolio value rose 13% quarter-over-quarter to $1.28B.

Based on Camber Capital Management's 13F filing for Q1 2014, filed 15 May 2014.